Epizootic haemorrhagic disease virus antibody and antigen (recombinant protein)

Diagnostic anti-Epizootic haemorrhagic disease virus antibodies pairs and antigen for animal health (animal Cat/Feline, Dog/Canine, Bovines/Cattle, Ovines/Sheep, Caprine/Goat, Fish, Swine/Porcine/Pig, Avian/Bird/Poultry, Deer infectious disease Epizootic hemorrhagic disease) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Multiple species disease testing products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-VT-P273-Ag01 Recombinant Epizootic haemorrhagic disease virus protein $3090.00
GMP-VT-P273-Ab01 Anti-Epizootic haemorrhagic disease virus mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P273-Ab02 Anti-Epizootic haemorrhagic disease virus mouse monoclonal antibody (mAb) $3090.00

Size: 1mg | 10mg | 100mg



Product Description

Cat No. GMP-VT-P273-Ag01
Product Name Recombinant Epizootic haemorrhagic disease virus protein
Pathogen Epizootic haemorrhagic disease virus
Expression platform E.coli
Isotypes Recombinant Antigen
Bioactivity validation Anti-Epizootic haemorrhagic disease virus antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Epizootic haemorrhagic disease virus level test of animal Cat/Feline, Dog/Canine, Bovines/Cattle, Ovines/Sheep, Caprine/Goat, Fish, Swine/Porcine/Pig, Avian/Bird/Poultry, Deer infectious disease with Epizootic hemorrhagic disease.
Tag His
Product description Recombinant Epizootic haemorrhagic disease virus proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P273-Ab01,GMP-VT-P273-Ab02
Pathogen Epizootic haemorrhagic disease virus
Product Name Anti-Epizootic haemorrhagic disease virus mouse monoclonal antibody (mAb)
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation Recombinant Epizootic haemorrhagic disease virus antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Epizootic haemorrhagic disease virus antibodies in Epizootic haemorrhagic disease virus level test of animal Cat/Feline, Dog/Canine, Bovines/Cattle, Ovines/Sheep, Caprine/Goat, Fish, Swine/Porcine/Pig, Avian/Bird/Poultry, Deer infectious disease with Epizootic hemorrhagic disease.
Product description Anti-Epizootic haemorrhagic disease virus mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Epizootic haemorrhagic disease virus antibodies./td>
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Pathogen


    Epizootic hemorrhagic disease virus (EHDV) is a significant pathogen that is found in various parts of the world, and it primarily infects ruminant species such as deer, cattle, sheep, and goats. EHDV belongs to the Reoviridae family, which is a group of non-enveloped viruses that have a multilayered protein capsid enclosing 10-12 segments of double-stranded RNA.

    The structure of EHDV consists of two primary proteins, including VP2 and VP7. VP2, the outer capsid protein, is responsible for viral entry into host cells. VP7 is the inner capsid protein, which facilitates viral replication and assembly. The combination of the VP2 and VP7 proteins enables EHDV to target specific cells and replicate efficiently.

    EHDV causes Epizootic hemorrhagic disease (EHD), a severe disease characterized by high fever, lethargy, erosive and ulcerative lesions in the mouth, hemorrhages, and ultimately death in most cases. The clinical manifestations of EHD can be variable depending on the strain of the virus and the host species. EHDV can develop different serotypes, each with its unique genetic makeup and antigenic properties that have different pathogenicity levels.

    EHDV transmission occurs through midges (Culicoides spp.), small biting flies that are widespread throughout most of the world and often take a blood meal from infected animals, allowing them to carry the virus and transmit it to other animals. Seasonal changes and environmental factors, such as temperature and humidity, affect the population density of Culicoides spp. and, consequently, the incidence and severity of EHD outbreaks.

    Diagnosis of EHDV infection can be challenging due to the varied clinical signs and the similarities of EHDV with other diseases that cause similar symptoms in animals. In animals suspected of EHDV infection, the diagnosis is typically confirmed through a combination of clinical signs and laboratory testing. As mentioned previously, ELISA and PCR are the most commonly used tests for diagnosing EHDV infection. Virus isolation, serology and histopathology can also be used to confirm a diagnosis of EHDV infection.

    Currently, there is no specific treatment for EHDV infection other than supportive care and management. The use of insecticides, mosquito repellents, and protective clothing can help reduce the risk of transmission of EHDV and other diseases transmitted by Culicoides spp. Vaccination against EHDV is available, but it varies depending on the geographic location, season, and serotype of EHDV involved.

    In conclusion, EHDV is a significant pathogen that poses a severe threat to ruminants worldwide. Understanding the structure, clinical features, and transmission of EHDV is essential for its management and control. The development of new and more effective diagnostic tools and treatments will ultimately aid in controlling the spread of EHDV and preventing future outbreaks.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.